# PeptideScanner evidence objects: Glepaglutide

Every published version of the records placed with Glepaglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json. Selected public evidence only; not medical advice.

- Objects: 9
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03279302-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT03279302

> PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03279302-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03279302-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03279302-glepaglutide-v1
- Content SHA-256: `fc0e4b8e72e5357ecd81bbe4d40015d6937fb87fb1cc139871994867993b4388`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03279302 ([`ctg-observation-nct03279302-2017-12-22-dc50408f6a0e`](#source-ctg-observation-nct03279302-2017-12-22-dc50408f6a0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03279302-2017-12-22-dc50408f6a0e`](#source-ctg-observation-nct03279302-2017-12-22-dc50408f6a0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03279302-2017-12-22-dc50408f6a0e`](#source-ctg-observation-nct03279302-2017-12-22-dc50408f6a0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03279302-2017-12-22-dc50408f6a0e`](#source-ctg-observation-nct03279302-2017-12-22-dc50408f6a0e))

### Sources

<a id="source-ctg-observation-nct03279302-2017-12-22-dc50408f6a0e"></a>
- **ClinicalTrials.gov record NCT03279302 · retained source version 2017-12-22:dc50408f6a0efc0c865db83cf7865bb605dfb21efc12d9e14189a8f404facd54** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03279302) (`ctg-observation-nct03279302-2017-12-22-dc50408f6a0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03279302." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03279302-glepaglutide-v1 SHA-256: fc0e4b8e72e5357ecd81bbe4d40015d6937fb87fb1cc139871994867993b4388.

---

<a id="clinicaltrials-gov-nct03690206-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT03690206

> PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03690206-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03690206-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03690206-glepaglutide-v1
- Content SHA-256: `cd8b3f8c67790d604190bc8f12762d82f0243d7bb08ffbf7b630e823d1b0c770`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03690206 ([`ctg-observation-nct03690206-2025-07-17-3e2aff5817a1`](#source-ctg-observation-nct03690206-2025-07-17-3e2aff5817a1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03690206-2025-07-17-3e2aff5817a1`](#source-ctg-observation-nct03690206-2025-07-17-3e2aff5817a1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03690206-2025-07-17-3e2aff5817a1`](#source-ctg-observation-nct03690206-2025-07-17-3e2aff5817a1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03690206-2025-07-17-3e2aff5817a1`](#source-ctg-observation-nct03690206-2025-07-17-3e2aff5817a1))

### Sources

<a id="source-ctg-observation-nct03690206-2025-07-17-3e2aff5817a1"></a>
- **ClinicalTrials.gov record NCT03690206 · retained source version 2025-07-17:3e2aff5817a151ae789399cdd4bd45d445559960e7ea0c24fc977217631eb957** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03690206) (`ctg-observation-nct03690206-2025-07-17-3e2aff5817a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03690206." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03690206-glepaglutide-v1 SHA-256: cd8b3f8c67790d604190bc8f12762d82f0243d7bb08ffbf7b630e823d1b0c770.

---

<a id="clinicaltrials-gov-nct03905707-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT03905707

> PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03905707-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03905707-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03905707-glepaglutide-v1
- Content SHA-256: `3d9a6c3f1959149b0605c4aaf66de5ead57f085a70c466f254145f25516139ef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03905707 ([`ctg-observation-nct03905707-2026-09-08-11059977e74d`](#source-ctg-observation-nct03905707-2026-09-08-11059977e74d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03905707-2026-09-08-11059977e74d`](#source-ctg-observation-nct03905707-2026-09-08-11059977e74d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct03905707-2026-09-08-11059977e74d`](#source-ctg-observation-nct03905707-2026-09-08-11059977e74d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03905707-2026-09-08-11059977e74d`](#source-ctg-observation-nct03905707-2026-09-08-11059977e74d))

### Sources

<a id="source-ctg-observation-nct03905707-2026-09-08-11059977e74d"></a>
- **ClinicalTrials.gov record NCT03905707 · retained source version 2026-09-08:11059977e74d5a72c90793b0c13b1c07753e002ccbfea3f4c86b86e077f7ccc0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03905707) (`ctg-observation-nct03905707-2026-09-08-11059977e74d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03905707." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct03905707-glepaglutide-v1 SHA-256: 3d9a6c3f1959149b0605c4aaf66de5ead57f085a70c466f254145f25516139ef.

---

<a id="clinicaltrials-gov-nct04178447-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT04178447

> PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04178447-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04178447-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04178447-glepaglutide-v1
- Content SHA-256: `fa1cd0384bc2f258e1800f02dc9a129f5f670b5ddf4e426e2b997a350c9d19fa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04178447 ([`ctg-observation-nct04178447-2020-11-18-9b37bf708af5`](#source-ctg-observation-nct04178447-2020-11-18-9b37bf708af5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04178447-2020-11-18-9b37bf708af5`](#source-ctg-observation-nct04178447-2020-11-18-9b37bf708af5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04178447-2020-11-18-9b37bf708af5`](#source-ctg-observation-nct04178447-2020-11-18-9b37bf708af5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04178447-2020-11-18-9b37bf708af5`](#source-ctg-observation-nct04178447-2020-11-18-9b37bf708af5))

### Sources

<a id="source-ctg-observation-nct04178447-2020-11-18-9b37bf708af5"></a>
- **ClinicalTrials.gov record NCT04178447 · retained source version 2020-11-18:9b37bf708af58cd3f0f5102128716c076926d303136fdb12411ff0dffb25ea2d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04178447) (`ctg-observation-nct04178447-2020-11-18-9b37bf708af5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04178447." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04178447-glepaglutide-v1 SHA-256: fa1cd0384bc2f258e1800f02dc9a129f5f670b5ddf4e426e2b997a350c9d19fa.

---

<a id="clinicaltrials-gov-nct04318743-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT04318743

> PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04318743-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-07-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04318743-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04318743-glepaglutide-v1
- Content SHA-256: `4a3575db569620ba03c96928d56f8389e625b7bba1d81bd92afea496900c3de6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04318743 ([`ctg-observation-nct04318743-2021-07-14-c3c401151845`](#source-ctg-observation-nct04318743-2021-07-14-c3c401151845))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04318743-2021-07-14-c3c401151845`](#source-ctg-observation-nct04318743-2021-07-14-c3c401151845))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04318743-2021-07-14-c3c401151845`](#source-ctg-observation-nct04318743-2021-07-14-c3c401151845))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04318743-2021-07-14-c3c401151845`](#source-ctg-observation-nct04318743-2021-07-14-c3c401151845))

### Sources

<a id="source-ctg-observation-nct04318743-2021-07-14-c3c401151845"></a>
- **ClinicalTrials.gov record NCT04318743 · retained source version 2021-07-14:c3c40115184512d49b736177a5b21cfecdae03efd4ffc9b77d01b40f6bcb8b52** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04318743) (`ctg-observation-nct04318743-2021-07-14-c3c401151845`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04318743." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04318743-glepaglutide-v1 SHA-256: 4a3575db569620ba03c96928d56f8389e625b7bba1d81bd92afea496900c3de6.

---

<a id="clinicaltrials-gov-nct04881825-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT04881825

> PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04881825-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04881825-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04881825-glepaglutide-v1
- Content SHA-256: `432ea23e90e7ff2637d05fbbcf20c75534bf78ed63bba4a8ebf6aaaa1e05bb11`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04881825 ([`ctg-observation-nct04881825-2026-09-08-eaf163f36be9`](#source-ctg-observation-nct04881825-2026-09-08-eaf163f36be9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04881825-2026-09-08-eaf163f36be9`](#source-ctg-observation-nct04881825-2026-09-08-eaf163f36be9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04881825-2026-09-08-eaf163f36be9`](#source-ctg-observation-nct04881825-2026-09-08-eaf163f36be9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04881825-2026-09-08-eaf163f36be9`](#source-ctg-observation-nct04881825-2026-09-08-eaf163f36be9))

### Sources

<a id="source-ctg-observation-nct04881825-2026-09-08-eaf163f36be9"></a>
- **ClinicalTrials.gov record NCT04881825 · retained source version 2026-09-08:eaf163f36be9700764a5ef47014a2bce6716739462518d1ce3cadf802d2d7c04** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04881825) (`ctg-observation-nct04881825-2026-09-08-eaf163f36be9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04881825." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04881825-glepaglutide-v1 SHA-256: 432ea23e90e7ff2637d05fbbcf20c75534bf78ed63bba4a8ebf6aaaa1e05bb11.

---

<a id="clinicaltrials-gov-nct04991311-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT04991311

> PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04991311-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-11-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04991311-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04991311-glepaglutide-v1
- Content SHA-256: `ea347f08befd2190f6cf0f65a27aee058ab1521455966e201b07cfe9358ff85b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04991311 ([`ctg-observation-nct04991311-2024-11-22-7052534a6c8e`](#source-ctg-observation-nct04991311-2024-11-22-7052534a6c8e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04991311-2024-11-22-7052534a6c8e`](#source-ctg-observation-nct04991311-2024-11-22-7052534a6c8e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct04991311-2024-11-22-7052534a6c8e`](#source-ctg-observation-nct04991311-2024-11-22-7052534a6c8e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04991311-2024-11-22-7052534a6c8e`](#source-ctg-observation-nct04991311-2024-11-22-7052534a6c8e))

### Sources

<a id="source-ctg-observation-nct04991311-2024-11-22-7052534a6c8e"></a>
- **ClinicalTrials.gov record NCT04991311 · retained source version 2024-11-22:7052534a6c8ee0696d8734e5e5f23a1d20f87287c6e8b1b3cac450a9fdd07ebe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04991311) (`ctg-observation-nct04991311-2024-11-22-7052534a6c8e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04991311." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct04991311-glepaglutide-v1 SHA-256: ea347f08befd2190f6cf0f65a27aee058ab1521455966e201b07cfe9358ff85b.

---

<a id="clinicaltrials-gov-nct07197944-glepaglutide-v1"></a>

## ClinicalTrials.gov record NCT07197944

> PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07197944-glepaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07197944-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct07197944-glepaglutide-v1
- Content SHA-256: `b6be0cbb0467626803fa8ef1fe76aa4a9f6e32736b824956a314eb0b9e750229`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07197944 ([`ctg-observation-nct07197944-2026-09-29-d17b66ad0d02`](#source-ctg-observation-nct07197944-2026-09-29-d17b66ad0d02))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct07197944-2026-09-29-d17b66ad0d02`](#source-ctg-observation-nct07197944-2026-09-29-d17b66ad0d02))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide. ([`ctg-observation-nct07197944-2026-09-29-d17b66ad0d02`](#source-ctg-observation-nct07197944-2026-09-29-d17b66ad0d02))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07197944-2026-09-29-d17b66ad0d02`](#source-ctg-observation-nct07197944-2026-09-29-d17b66ad0d02))

### Sources

<a id="source-ctg-observation-nct07197944-2026-09-29-d17b66ad0d02"></a>
- **ClinicalTrials.gov record NCT07197944 · retained source version 2026-09-29:d17b66ad0d028f8ed1ae307ba724f47af9774ddda187807aa0977fb1675d8eb3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07197944) (`ctg-observation-nct07197944-2026-09-29-d17b66ad0d02`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07197944." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#clinicaltrials-gov-nct07197944-glepaglutide-v1 SHA-256: b6be0cbb0467626803fa8ef1fe76aa4a9f6e32736b824956a314eb0b9e750229.

---

<a id="pubmed-pmid-41816796-glepaglutide-v1"></a>

## Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.

> PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41816796-glepaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41816796-glepaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#pubmed-pmid-41816796-glepaglutide-v1
- Content SHA-256: `00e3475615ec40172f4b2cb660cea9a339a5d79a3a65cc6e813d6332af20528b`

### Claims and source pins

#### Headline

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. ([`pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7`](#source-pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7))

#### Summary

PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7`](#source-pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7))

#### Paragraph 1

PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7`](#source-pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7`](#source-pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7))

### Sources

<a id="source-pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7"></a>
- **Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial. · retained source version 1:2026-09-02:current:edf436b5b2a7a95e758e93ebedd17071036bdc1df73c58e72f50fb0fc2c837c1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41816796/) (`pubmed-observation-pmid-41816796-2026-09-02-edf436b5b2a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glepaglutide.json#pubmed-pmid-41816796-glepaglutide-v1 SHA-256: 00e3475615ec40172f4b2cb660cea9a339a5d79a3a65cc6e813d6332af20528b.

